Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026

6/17/24 4:08:10 PM ET

$VXRT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $VXRT alert in real time by email

— Cash runway extended into 2026 —

— Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million —

— Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs —

Get the next $VXRT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VXRT

Date	Price Target	Rating	Analyst
8/15/2024	$4.00	Outperform	Oppenheimer
12/29/2021	$13.00 → $12.00	Buy	Jefferies
11/2/2021	$15.00	Overweight	Cantor Fitzgerald
6/30/2021	$13.00 → $9.00	Buy → Neutral	B. Riley Securities
6/29/2021	$13.00 → $9.00	Buy → Neutral	B. Riley Securities
6/24/2021	$13.00	Buy	Jefferies

More analyst ratings

$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones index closed higher by around 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Vaxart The Trade: Vaxart, Inc. (NASDAQ:VXRT) Director W. Mark Watson bought a total of 20,000 shares at an average price of $0.68. To acquire these shares, it cost around $13,578. What's Happening: Vaxart announced Monday that proceeds from
6/21/24 8:22:05 AM ET
$AEI
$CLOV
$GLYC
$VXRT
Real Estate
Finance
Medical Specialities
Health Care
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 72.1% to $1.91 during Wednesday's regular session. The company's market cap stands at $4.8 million. Nexalin Technology (NASDAQ:NXL) shares increased by 43.06% to $1.08. The market value of their outstanding shares is at $8.0 million. Vaxart (NASDAQ:VXRT) shares rose 33.45% to $0.7. The market value of their outstanding shares is at $123.8 million. Sunshine Biopharma (NASDAQ:SBFM) stock increased by 28.92% to $0.39. The market value of their outstanding shares is at $7.4 million. Portage Biotech (NASDAQ:PRTG) shares increased by 25.0% to $0.3. The company's market cap stands at $5.9 million. Silk Road Medical (NASDAQ:SILK) shares
6/19/24 12:30:59 PM ET
$AZTR
$DMTK
$GOVX
$LPCN
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
Biotechnology: Electromedical & Electrotherapeutic Apparatus
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 50.0% to $1.12 during Tuesday's regular session. The company's market cap stands at $31.7 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 27.95% to $0.22. The company's market cap stands at $3.3 million. The company's, Q4 earnings came out yesterday. Vaxart (NASDAQ:VXRT) shares moved upwards by 27.83% to $0.67. The market value of their outstanding shares is at $118.6 million. Silk Road Medical (NASDAQ:SILK) shares moved upwards by 23.92% to $26.86. The company's market cap stands at $1.0 billion. Kintara Therapeutics (NASDAQ:KTRA) stock rose 18.1% to $0.21. The company's market cap stands at $11.6 million. Atri
6/18/24 12:31:11 PM ET
$AMIX
$ATRC
$AZTR
$DMTK
Medical/Dental Instruments
Health Care
Biotechnology: Pharmaceutical Preparations
Medical Specialities

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the third quarter of 2024. "Our successful initiation of sentinel cohort dosing is a testament to our rapid execution in helping to ensure that we remain on track to meet the milestones of our Biomedical Advanced Research Development Authority (BARDA) contract," said Steven Lo, Vaxart's Chi
11/13/24 4:01:00 PM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, November 13, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13749666 Investors may submit written questions in advance of
11/7/24 8:00:00 AM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results
BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats Solid financial position enables Vaxart to execute on multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the second quarter of 2024. "We achieved meaningful progress on our clinical, regulatory and operational goals during the first half of 2024," said Steven Lo, Vaxart's Chief Executive Officer. "Most s
8/8/24 4:01:00 PM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$VXRT
Press Releases

Fastest customizable press release news feed in the world

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that on November 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 91,500 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart. The awards consisted of stock options to purchase an aggregate of 61,000 shares of Vaxart's common stock, which vest as to 1/4th of the total shares on the one-year anniversary of the grant date, and as to 1/48th of the total shares on each month thereafter, and have a per share exercise price equal to the
11/19/24 8:00:00 AM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the third quarter of 2024. "Our successful initiation of sentinel cohort dosing is a testament to our rapid execution in helping to ensure that we remain on track to meet the milestones of our Biomedical Advanced Research Development Authority (BARDA) contract," said Steven Lo, Vaxart's Chi
11/13/24 4:01:00 PM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, November 13, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13749666 Investors may submit written questions in advance of
11/7/24 8:00:00 AM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$VXRT
Leadership Updates

Live Leadership Updates

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Ch
3/6/24 8:00:00 AM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Vaxart Appoints W. Mark Watson to its Board of Directors
Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that W. Mark Watson was appointed to the Company's Board of Directors, effective August 4, 2022. Mr. Watson will become Chair of the Company's Audit Committee, effective October 1. Robert A. Yedid, a member of the Board and the Audit Committee, was appointed Interim Chairperson of the Audit Committee, to serve until Mr. Watson becomes Chair. "We are very excited to welcome Mark to the Board, whose skills and experience will help us advance our strategy to develop potentially transformative oral pi
8/8/22 8:00:00 AM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective today. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. He joins Vaxart from BioMarin Pharmaceutical Inc., where he served as VP, Deputy General Counsel since 2018. "Ed has more than 25 years of experience advising biotech and pharma companies, and we are excited to benefit from his acumen as
2/14/22 8:00:00 AM ET
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026

Chat with this insight

Recent Analyst Ratings for $VXRT

$VXRT SEC Filings

SEC Form 10-Q filed by Vaxart Inc

Vaxart Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 424B5 filed by Vaxart Inc

$VXRT Market Insights

Live Market Insights

$VXRT Financials

Live finance-specific insights

$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

$VXRT Press Releases

Fastest customizable press release news feed in the world

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

$VXRT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Watson W. Mark bought $13,578 worth of shares (20,000 units at $0.68), increasing direct ownership by 34% to 78,125 units (SEC Form 4)

$VXRT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$VXRT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$VXRT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Director Watson W. Mark bought $13,578 worth of shares (20,000 units at $0.68), increasing direct ownership by 34% to 78,125 units (SEC Form 4)

Chief Financial Officer Lee Phillip E covered exercise/tax liability with 2,007 shares, decreasing direct ownership by 0.83% to 239,801 units (SEC Form 4)

Director Wheadon David E. was granted 16,000 shares, increasing direct ownership by 108% to 30,750 units (SEC Form 4)

Oppenheimer initiated coverage on Vaxart with a new price target

Jefferies resumed coverage on Vaxart with a new price target

Cantor Fitzgerald initiated coverage on Vaxart with a new price target

SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

SEC Form SC 13G filed by Vaxart Inc

SEC Form SC 13G filed by Vaxart Inc

$VXRT Leadership Updates

Live Leadership Updates

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Vaxart Appoints W. Mark Watson to its Board of Directors

Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

Recent Analyst Ratings for
$VXRT

$VXRT
SEC Filings

$VXRT
Market Insights

$VXRT
Financials

$VXRT
Press Releases

$VXRT
Insider Purchases

$VXRT
Insider Trading

$VXRT
Analyst Ratings

$VXRT
Large Ownership Changes

$VXRT
Leadership Updates